Hyundai Bioland

현대바이오랜드 · 052260

Materials Chemicals · KOSDAQ

Small-cap

Market cap US$82M (₩113.1B)

Overview

Hyundai Bioland makes ingredients derived from natural sources, such as hyaluronic acid, beta-glucan, and plant-based collagen, used in cosmetics, health supplements, pharmaceutical actives, and medical devices including dental bone-regeneration materials.

It supplies these ingredients to cosmetics companies, pharmaceutical firms, and healthcare brands globally, and also distributes premium international health supplement brands exclusively within South Korea. Listed on KOSDAQ, Korea's tech and small-cap board, its cosmetics ingredient business accounts for the largest share of revenue, with brand distribution and medical devices making up most of the remainder.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$94.6M
▲ +9.2% YoY
Operating profit · FY2025
US$9.2M
▼ −22.3% YoY
Net income · FY2025
US$183.1K
▼ −95.6% YoY

Revenue

  • FY2023US$73.7M
  • FY2024US$86.6M
  • FY2025US$94.6M

Operating profit

  • FY2023US$5.1M
  • FY2024US$11.9M
  • FY2025US$9.2M

Net income

  • FY2023US$5.8M
  • FY2024US$4.1M
  • FY2025US$183.1K

Key ratios (FY2025)

ROE
0.2%
Debt/Eq
22.6%
Op. margin
9.7%
Net margin
0.2%
Rev. YoY
▲ +9.2%

Why it matters

The company exclusively distributes Nestlé Health Science brands, including Solgar and Vital Proteins, in South Korea, operating dedicated retail shops under that partnership.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.